1. A process for preparing an immunoglobulin preparation, wherein the process comprises adding proline to an initial immunoglobulin preparation comprising less than 15% (mv) immunoglobulin, and concentrating the initial immunoglobulin preparation to prepare a final immunoglobulin preparation comprising at least 18% (mv) immunoglobulin, and wherein proline is added such that the viscosity of the final immunoglobulin preparation is less than 13 mPa\xb7 s as measured by a falling ball viscosimeter at 20.0\xb0 C.
2. The process according to claim 1, wherein the proline is L-proline.
3. The process according to claim 1, wherein the immunoglobulin of the immunoglobulin preparation consists essentially of IgG.
4. The process according to claim 1, wherein the proline is added to the initial immunoglobulin preparation such that the concentration of proline in the final immunoglobulin preparation ranges from 10 to 1000 mmoll.
5. The process according to claim 1 wherein the final immunoglobulin preparation ranges from 18% to 20% (mv) immunoglobulin.
6. A process for preparing an immunoglobulin preparation, wherein the process comprises adding proline to an initial immunoglobulin preparation comprising less than 15% (mv) immunoglobulin, and concentrating the initial immunoglobulin preparation to prepare a final immunoglobulin preparation comprising at least 20% (mv) immunoglobulin, and wherein proline is added to the initial immunoglobulin preparation such that the viscosity of the final immunoglobulin preparation is less than 19 mPa\xb7 s as measured by a falling ball viscosimeter at 20.0\xb0 C.
7. The process of claim 1, wherein no viscosity-lowering agents or stabilizing agents are added to the initial immunoglobulin preparation other than proline.
8. The process of claim 3, wherein the IgG is obtained from pooled human plasma from at least 1000 donors.
9. The process of claim 4, wherein proline is added to the initial immunoglobulin preparation such that the concentration of proline in the final immunoglobulin preparation is from 100 to 500 mmoll.
10. The process of claim 9, wherein proline is added to the initial immunoglobulin preparation such that the concentration of proline in the final immunoglobulin preparation is about 250 mmoll.
11. The process of claim 5, wherein proline is added to the initial immunoglobulin preparation such that the viscosity of the final immunoglobulin preparation is less than 9 mPa\xb7 s as measured by a falling ball viscosimeter at 20.0\xb0 C.
12. The process of claim 6, wherein proline is added to the initial immunoglobulin preparation such that the viscosity of the final immunoglobulin preparation is less than 13 mPa\xb7 s as measured by a falling ball viscosimeter at 20.0\xb0 C.
13. The process of claim 12, wherein the final immunoglobulin preparation comprises about 20% (mv) immunoglobulin.
14. The process of claim 1, wherein the final immunoglobulin preparation is suitable for subcutaneous administration to patients.
15. The process of claim 14, wherein the final immunoglobulin preparation may be administered by direct manual push from a syringe.
16. The process of claim 6, wherein no viscosity-lowering agents or stabilizing agents are added to the initial immunoglobulin preparation other than proline.
17. The process of claim 6, wherein proline is added to the initial immunoglobulin preparation such that the concentration of proline in the final immunoglobulin preparation is from 100 to 500 mmoll.
18. The process of claim 17, wherein proline is added to the initial immunoglobulin preparation such that the concentration of proline in the final immunoglobulin preparation is about 250 mmoll.
19. The process of claim 6, wherein the immunoglobulin of the immunoglobulin preparation consists essentially of IgG wherein the IgG is obtained from pooled human plasma from at least 1000 donors.
20. The process of claim 6, wherein the final immunoglobulin preparation is suitable for subcutaneous administration to patients.
21. The process of claim 20, wherein the final immunoglobulin preparation may be administered by direct manual push from a syringe.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A vehicle structure comprising:
a rear roof rail which is placed in a reward position of a center pillar and which forms a rear end of a roof of a vehicle; and
a connector which connects a closed section formed on the center pillar and a closed section formed on said rear roof rail so that the first and the second closed sections are formed into a continuous closed section and which includes a side roof rail part which forms a portion of a side roof rail that extend in the longitudinal direction of the vehicle.
2. A vehicle structure according to claim 1, wherein said connector and the side roof rail form a bulkhead at a connection between said side roof rail part of said connector and the side roof rail.
3. A vehicle structure according to claim 1, wherein said connector and a reinforcement of the center pillar are formed as a unit.
4. A vehicle structure according to claim 1, wherein said connector forms a portion of said rear roof rail part.
5. A vehicle structure according to claim 1, wherein:
said connector and a reinforcement of the center pillar are formed as a unit; and
said connector forms a portion of said rear roof rail part.